Menu
Close
Primary links
Newsroom Home
Press Releases
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
Biosimilars
Collaborations
Events & Webcasts
Sign up for Alerts
All Press Releases
Login
All Press Releases
Filter by
<Any>
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
-Year
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
Search
Biogen Idec Highlights Progress and Breadth of Pipeline Programs at R&D Day
3/25/09 8:30 am EDT
Biogen Idec Announces March 25 Webcast of Research & Development Day
3/18/09 4:03 pm EDT
Biogen Idec Announces Head of Research and Development Dr. Cecil B. Pickett to Retire
3/12/09 4:01 pm EDT
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
3/11/09 4:30 pm EDT
Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference
3/10/09 11:05 am EDT
Biogen Idec Names Michael Lytton Executive Vice President of Business Development
2/23/09 4:00 pm EST
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
2/9/09 2:00 am EST
Biogen Idec Reports Full Year and Fourth Quarter 2008 Results
2/6/09 7:34 am EST
Biogen Idec Receives Shareholder Proposal
2/6/09 7:32 am EST
Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009
1/9/09 11:51 am EST
« first
‹ previous
…
51
52
53
54
55
56
57
58
59
…
next ›
last »
all Press Releases
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Biogen Idec Announces Head of Research and Development Dr. Cecil B. Pickett to Retire
3/12/09 4:01 pm EDT
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
3/11/09 4:30 pm EDT
Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference
3/10/09 11:05 am EDT
Biogen Idec Names Michael Lytton Executive Vice President of Business Development
2/23/09 4:00 pm EST
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
2/9/09 2:00 am EST
Biogen Idec Reports Full Year and Fourth Quarter 2008 Results
2/6/09 7:34 am EST
Biogen Idec Receives Shareholder Proposal
2/6/09 7:32 am EST
Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009
1/9/09 11:51 am EST
Biogen Idec to Present at the 27th Annual J.P. Morgan Healthcare Conference
1/6/09 12:47 pm EST
Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
1/5/09 1:49 pm EST
« first
‹ previous
…
51
52
53
54
55
56
57
58
59
…
next ›
last »